drugset / Trial / NCT04060407
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
Phase 1/2
Withdrawn
Merck & Co., Inc.
Huntsman Cancer Institute · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ib/II clinical trial to test safety and efficacy of combining CD24Fc with ipilimumab and nivolumab to decrease irAE, with built-in interim analyses, and safety and response stopping rules.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2022-12-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD24Fc | Protein / enzyme biologic | 480 mg | Intravenous |
| Background | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |